Based on recent studies, might neurovascular and cognitive decline in the brain be reduced by pharmacologically targeting the cyclophilin A-nuclear factor κB-matrix metalloproteinase-9 axis, as has been proposed for APOE4-mediated neurovascular injury [9]? The gene discussed is MMP9; the disease is Mental deterioration.